2 unknown, 1 completed, 1 not yet recruiting. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
Follow Empros Pharma AB: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial With EMP16 in Preparation for Late Phase Studies EMP16-02 120 mg orlistat/40 mg acarbose, Alli® 60 mg, Vi-Siblin® S - Overweight or Obese, Obesity and Overweight | Phase 2 | Not yet recruiting | Empros Pharma AB | 39 | 2025-05-20 | 2025-05-28 |
| A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers Xenical® vs EMP 22, EMP 22 vs Xenical®, EMP 16 vs Xenical® - Overweight or Obesity | Phase 1 | Unknown | Empros Pharma AB | 20 | 2023-09-22 | 2023-10-04 |
| Study Exploring the Supportive Effect of Acarbose in Weight Management EMP16-120/40, MR orlistat 120 mg, Conventional orlistat 120 mg, - Overweight or Obesity | Phase 2 | Unknown | Empros Pharma AB | 320 | 2023-04-18 | 2024-02-20 |
| A Proof of Concept Trial in Overweight and Obese Patients, Investigating Effect of EMP16-02 on Body Weight (Primary) EMP16-02 120 mg orlistat/40 mg acarbose, EMP16-02 150 mg orlistat/50 mg acarbose, Placebo - Overweight or Obesity | Phase 1 / Phase 2 | Completed | Empros Pharma AB | 156 | 2020-05-07 | 2022-04-04 |
Obesity (4) · Overweight (4)
Orlistat (2) · maltodextrin (1)
Sweden (3)
Helena Litorp, MD, PhD (2) · Daniel Wilhelms, MD, PhD (1)
2023 (1)